Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Study of FID-022 in Participants with Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Fidaxomicin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Fidaxomicin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Fulgent Genetics
Deal Size : $100.0 million
Deal Type : Acquisition
Details : FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline polymer excipient designed to enhance PK, biodistribution, and tolerability. The PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpe...
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Fulgent Genetics
Deal Size : $100.0 million
Deal Type : Acquisition